Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

Biosimilars Rheumatology Roundup: June 2025

July 01, 2025

HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer

March 12th 2024

By Cameron Santoro

Article

A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.

The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability

March 11th 2024

By Kashyap Patel, MD

Article

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.

Biosimilars vs Bad Patents: Accessibility, Key Court Cases With Ha Kung Wong

March 10th 2024

By Cameron Santoro

Video

Intellectual property attorney, Ha Kung Wong, JD, discusses concerns about "bad patents" hindering biosimilar access, but assures that the FDA and United States Patent and Trademark Office are working to improve the system.

Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5

March 9th 2024

By Deana Ferreri, PhD

Article

The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.

The Top 5 Biosimilar Articles for the Week of March 4

March 8th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 4, 2024.

FDA Green Lights Second Tocilizumab Biosimilar

March 7th 2024

By Skylar Jeremias

Article

The FDA has approved Fresenius Kabi's tocilizumab biosimilar (Tyenne; tocilizumab-aazg), making it the second tocilizumab biosimilar overall and first tocilizumab biosimilar to be approved with both intravenous and subcutaneous administration options.

Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo

March 6th 2024

By Skylar Jeremias

Article

Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.

FDA Approves First Denosumab Biosimilars

March 5th 2024

By Skylar Jeremias

Article

Sandoz’ Wyost/Jubbonti (denosumab-bddz) references Prolia and Xgeva and can be used to treat osteoporosis and hypercalcemia as well as prevent skeletal-related events associated with bone metastases from solid tumors.

QL1207 Biosimilar Shows Equivalent Efficacy, Safety to Aflibercept in Treating nAMD

March 5th 2024

By Cameron Santoro

Article

A Chinese phase 3 trial found biosimilar QL1207 to be as effective and safe as reference aflibercept (Eylea) for the treatment of neovascular age-related macular degeneration (nAMD).

BioRationality: EMA Announces Readiness to Waive Comparative Efficacy Studies of Biosimilars

March 4th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive regulatory approval.